* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download How does inflammation contribute to pathogenesis of atherosclerosis.
Survey
Document related concepts
Transcript
How does inflammation contribute to pathogenesis of atherosclerosis Petri Kovanen MD PhD Wihuri Research Institute Helsinki, Finland Joint EAS-ESC Session: (14:00 - 14:22) in Belgrade room ESC STOCKHOLM 30.8.2010 Inflammation and atherosclerosis - an early start Rudolf Virchow 1821-1902 Endarteritis deformans “The development of an atheroma is a consequence of an inflammatory process in the arterial intima, and a local reactive fibrotic thickening ensues when the inflammatory process stimulates the connective tissue cells in the intima to proliferate” Infection and atherosclerosis Sir William Osler 1908 Bacteria: Chl. pneumoniae, H. pylori, oral pathogens (the ”bacterial burden”) Viruses: CMV, HSV1, HSV2, adeno, coxsackie, influenza A, hepatitis type A • • • • Epidemiological studies Demonstration of microbes in the atheromas Experiments with animals Prospective studies in patient populations • Studies with antibiotics: negative • Development of vaccines! Against what? Exogenous antigen ? or Endogenous antigen = auto-antigen? Immunity and atherosclerosis 20 years ago : T cells Original Conclusions: HLA-DR staining DR-inducing cytokine must be present in plaque IFN-ɣ known to induce DR DR+ Endothelium IFN-ɣ is produced by activated T cells DR+ Macrophages Thus, immune activation in plaques - autoantigen presentation - inflammatory cytokines produced •Athero-Antigen? •Auto-Antigen? = oxLDL DR+ Smooth Muscle Cells HLA-DR in human plaque Jonasson & Hansson 1985 Fatty streak formation in human fetal aortas is enchanced by maternal hypercholesterolemia: evidence for early oxidation of LDL Apo-B (+) MDA-lysine (+) 4HNE-lysine (+) MDA-lysine (-) Normocholesterolemic mother Napoli C et al. JCI 1997 Adhesion of monocytes to activated endothelium Response to Retention Transmigration of monocytes Human coronary fatty streak: scavenging modified LDL Endothel Monocyte Macrophage Scavenger Rec Foam cell Herbert Stary Scavenger receptors - members of a bigger family Molecular components of the innate immune system (it is all about the ancient PATTERNS) RECEPTORS Pattern Recognition Receptors (PRRs) - Scavenger receptors SR-A and CD36 (cargo uptake) - Toll-like receptors (TLRs) (signaling) - Receptors for Avanced Glycosylation Products (RAGEs) LIGANDS Pathogen-Associated Molecular Patterns (PAMPs) Scavenger receptors recognize PathogenAssociated Molecular Patterns (PAMPS) "Recent danger" "Ancient danger" Binder et al JLR 2005 The TLRs are there for the lipoproteins of pathogens Lipoproteins take their toll on the host. Janeway CA Jr, Medzhitov R. Curr Biol. 1999 Dec 2;9(23):R879-82 TLR signaling pathway and its relevance to atherogenesis Endogen 1 TLR4 both endogenous ligands (autoantigens) and exogenous ligands (eg. LPS) 2 TLR4 signaling most relevant in atherosclerosis 3 Michelsen et al. J Immunol 2004;173:5901-5907 Exogen Exogen TLR expression in human atherosclerotic plaques Internal mammary arteries Carotid arteries Edfeldt, K. et al. Circulation 2002;105:1158-1161 What is the fate of cholesterol crystals in atherosclerosis? The Internet Pathology Laboratory, University of Utah - Cholesterol crystals and immune cells abundant in the lesions - IL-1β protein ↑ during lesion progression - Knocking out IL-1β or IL-1β receptor1 > atherosclerosis ↓ Macrophages phagocytose cholesterol crystals (CHC) CHC Bright field: Arrows indicate chol.crystals Confocal: Reflection (chol.crystals) Nucleus (Hoechst) Cell membrane (CTXb-647) Optical thickness 0.7 μm CHC + cytD Cholesterol crystals induce IL-1β secretion in the presence of a TLR ligand Monocytes Macrophages The NLRP3 inflammasome IL-1β macrophage IL-1β Hit #1 LPS TLR proIL-1β caspase-1 ASC NLRP3 receptor NF-κβ IL1B stress signals cholesterol crystals Hit #2 Novel pathways of inflammation: cholesterol crystals NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. Nature. 2010 Apr 29;464(7293):1357-61 Fig. 1 Cholesterol crystals appear in early atherosclerotic lesions Heterogeneity of human macrophages (CD68): GM and M + GM-CSF + M-CSF GM-Mac phenotype (CD14 -) M-Mac phenotype (CD14 +) Waldo et al. Am J Pathol 2008;172:1112-6 Heterogeneity of human macrophages (all CD68+) Human coronary artery atherosclerotic lesion CD14 (+) elongated CD14 (-) rounded M GM Waldo et al. Am J Pathol 2008;172:1112-6 Heterogeneity of human macrophages: The GM and M colony stimulating factors (CSFs) The GM-Mac phenotype that predominates in normal intima expresses genes known to mediate reverse cholesterol transport and macrophage emigration from the vessel wall. The M-Mac phenotype that predominates in diseased intima is deficient in the same atheroprotective genes but expresses proinflammatory genes. Waldo et al. Am J Pathol 2008;172:1112-6 From M-Mac to M1 and M2 another level of complexity Macrophage Monocyte Th1 M-CSF IFN-g + LPS IL-4 M1 pro-athero M2 anti-athero Th2 Martinez et al. J Immunol 2006 Resolution of inflammation: Th2-driven Infl. Cytokine production Efferocytosis M2 M1 Macrophage death and defective inflammation resolution in atherosclerosis. Tabas I. Nat Rev Immunol. 2010 Jan;10(1):36-46 The switch from early to advanced atherosclerosis M2 M1 Macrophage death and defective inflammation resolution in atherosclerosis. Tabas I. Nat Rev Immunol. 2010 Jan;10(1):36-46 Formation of a vulnerable plaque: defective clearance of apoptotic foam cells Macrophage death and defective inflammation resolution in atherosclerosis. Tabas I. Nat Rev Immunol. 2010 Jan;10(1):36-46 Rupture-prone plaque: high-risk plaque The ”thin-cap fibroatheroma” inflammation fibrosis thin cap lipid-rich core What is the physiological level of LDLcholesterol? Leads to regression of plaque = curative treatment mmol/l 18 8 3.5 3.0 2.5 2.0 1 mM =40mg/dL Nobel Prize-winners Brown ja Goldstein, Dallas Texas